Navigation Links
K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
Date:10/20/2010

ension of the production and shipment of all of the products that it manufactures (other than the Potassium Chloride products that are the subject of the FDA letter received September 8, 2010) and the related nationwide recall affecting all of the other products that it manufactures, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Background – Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Form 10-Q;
  • the possibility of further reducing the Company's operations, including further reductions of its employee base and significantly curtailing some or all of its efforts to meet the consent decree's requirements and return its approved products to market in order to maintain and attempt to increase its limited cash and financial resources, and related costs and accounting charges from taking such actions;
  • the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and de
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
    (Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
    (Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
    Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
    ... Emdeon (NYSE: EM ), a leading provider of healthcare ... participate in the Piper Jaffray Annual Health Care Conference to be ... The "fireside chat", featuring Tracy Bahl, executive chairman, will begin at ... live audio webcast will be available in the Investors section of ...
    ... , BURLINGTON, Mass., Nov. 17 Palomar Medical ... announce the immediate availability of the Groove Optic for ... significant advancement in fractional ablative skin resurfacing by creating ... ablative tissue coverage while preserving the benefits of fractional ...
    Cached Medicine Technology:New! The Groove Optic(TM) for the Lux2940(TM): A Breakthrough in Fractional Skin Resurfacing 2New! The Groove Optic(TM) for the Lux2940(TM): A Breakthrough in Fractional Skin Resurfacing 3
    (Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
    (Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
    (Date:1/22/2015)... Step into a macabre world where plants ... Virginia. Wicked Plants, the Museum’s latest featured exhibition, opens ... carnivorous and diabolical plants inside of a dilapidated, Victorian ... biochemical, physical and neurological processes between botanicals and the ...
    Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... Enable Greater Online ... between Physicians and Patients, ORLANDO, Fla., Feb. ... Conference, Allscripts, the leading provider of,clinical software, connectivity ... announced a collaboration between the National,ePrescribing Patient Safety ...
    ... It was announced that the,U.S. Court of Federal ... in favor of a child who regressed into ... contained the mercury-based preservative,thimerosal., Case documents state ... an underlying condition that ultimately led to,regressive encephalopathy ...
    ... There is a wealth of scientific literature available on ... there is a paucity of data to guide the ... the U.S. Food and Drug Administration (FDA) has recently ... with schizophrenia, few controlled data are available to help ...
    ... Ky., Feb. 28 Anthem Blue Cross and ... a 2007 BlueWorks(R),winner. A program of the Blue ... ways Blue Cross and Blue Shield companies are,working ... delivery,nationwide. The Harvard Medical School Department of Health ...
    ... has entered,into an agreement with VISICU, Inc., to ... remote monitoring tools, eICU,technology enables off-site critical care ... the clock. The voice, video and data,technology has ... and shorten hospital length of stay., A ...
    ... emerges from an altered pattern of brain development, and ... the brain to develop along a path that ultimately ... to be published in Biological Psychiatry on March 1st, ... to schizophrenia. , A prior genetic mapping study indicated ...
    Cached Medicine News:Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 2Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 3Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 4Health News:Government Concludes Vaccines Caused Autism 2Health News:Comparison of antipsychotic treatments in adolescents with schizophrenia 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:The Christ Hospital and VISICU Sign Agreement to Implement eICU(R) Program 2Health News:New genetic association with schizophrenia found by researchers 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: